drugset / Trial / NCT06768411
The Dosage Exploration Study of PEG-rhGH for Treating Short Stature in Prepubertal and Pubertal Children
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is dedicated to addressing the lack of research on the most effective dosage of long-acting growth hormone for children with short stature. By employing clinical trial design, we are committed to investigating the therapeutic benefits and safety profiles associated with varying doses of long-acting growth hormone. Our ultimate goal is to offer clinicians more precise treatment guidance and assist patients in attaining optimal growth and developmental outcomes.
Timeline
- Start
- 2025-01-15
- Primary completion
- 2026-12-30
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEG-rhGH | Protein / enzyme biologic | 0.2 mg/kg | — |
| Subject | PEG-rhGH | Protein / enzyme biologic | 0.22 mg/kg | — |